30 closest matches · ranked by relevance
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
Lung Cancer, Non-Small Cell · Metastatic Squamous Cell Carcinoma · Metastatic Non-Squamous Cell Carcinoma
Primary: Safety/Tolerability of ADXS-503 Monotherapy in Part A and ADXS-503 With Pembrolizumab in Part B: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE)…
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Lung Cancer
Primary: Progression-Free Survival — 4.1; 3.9 months
Lung Cancer · Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Primary: Overall Response Rate — 18; 1; 5; 12 Participants
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel — NA milligram
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Screen Success Rate — 655 Participants
Lung Cancer
Primary: Disease Response - Radiographic — 1; 16 participants
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Primary: Overall Response Rate — 13.5 percentage of participants
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Carcinoma, Non-small Cell
Primary: Progression-Free Survival (PFS) at Month 4: Cohort A — 76.9 percentage of participants
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 16.7; 8.3 Percentage of Participants
Lung Cancer
Primary: Overall Survival — 21 months
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary: Percentage of Participants With Objective Response (OR) — 39.5 Percentage of participants
Lung Cancer
Primary: Feasibility of Pharmacogenomics-based Treatment Assignment in the Cooperative Group Setting — 71 Participants
Lung Cancer
Primary: Overall Survival — 14.4; 15.9; 16.4 months — p=0.12
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 — 2.63; 1.94 Months — p=0.0103
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001